Art

J-GLOBAL ID：202002268506253110   Reference number：20A0872042

Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis

骨髄線維症患者における肺高血圧症と心機能に対するJanusキナーゼ1/2阻害剤ルキソリチニブの長期効果

Author (11)： Miyawaki Hiroshi (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Kioka Hidetaka (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Sato Kazuaki (Department of Pathology, Osaka University Graduate School of Medicine, Japan) ,  Kurashige Masako (Department of Pathology, Osaka University Graduate School of Medicine, Japan) ,  Ozawa Takayuki (Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan) ,  Shibayama Hirohiko (Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan) ,  Hikoso Shungo (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Morii Eiichi (Department of Pathology, Osaka University Graduate School of Medicine, Japan) ,  Yamauchi-Takihara Keiko (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan) ,  Yamauchi-Takihara Keiko (Health Care Center, Osaka University, Japan) ,  Sakata Yasushi (Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 59  Issue： 2  Page： 229-233(J-STAGE)  Publication year： 2020 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： cellular signal transduction

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A0872042&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (5)： onco-cardiology ,  pulmonary hypertension ,  tyrosine kinase inhibitor ,  cardiotoxicity ,  myelofibrosis

JST classification (2)： Drug therapy(=pharmacotherapy)for hematologic diseases in general  (GK05020P) ,  Cardiovascular system diseases  (GJ03000C)

Substance index (1)： Ruxolitinib

Reference (15)：

• 1. Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol 91: 50-58, 2016.
• 2. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91: 1262-1271, 2016.
• 3. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.
• 4. Tabarroki A, Lindner DJ, Visconte V, et al. Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis. Leukemia 28: 1486-1493, 2014.
• 5. Yamauchi-Takihara K, Kishimoto T. A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc Med 10: 298-303, 2000.

Terms in the title (8)： 骨髄線維症 ,  患者 ,  肺高血圧症 ,  心機能 ,  Janusキナーゼ1 ,  阻害剤 ,  ルキソリチニブ ,  長期効果